Symbol="ARDS"
AssetType="Common Stock"
Name="Aridis Pharmaceuticals Inc"
Description="Aridis Pharmaceuticals, Inc., an advanced-stage biopharmaceutical company, is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The company is headquartered in Los Gatos, California."
CIK="1614067"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="5941 OPTICAL COURT, SAN JOSE, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="11557000"
EBITDA="-28162000"
PERatio="None"
PEGRatio="None"
BookValue="-0.773"
DividendPerShare="0"
DividendYield="0"
EPS="-1.35"
RevenuePerShareTTM="0.136"
ProfitMargin="0"
OperatingMarginTTM="-9.58"
ReturnOnAssetsTTM="-1.075"
ReturnOnEquityTTM="0"
RevenueTTM="2986000"
GrossProfitTTM="-22605000"
DilutedEPSTTM="-1.35"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.088"
AnalystTargetPrice="10"
TrailingPE="-"
ForwardPE="2.061"
PriceToSalesRatioTTM="7.33"
PriceToBookRatio="5.4"
EVToRevenue="17.57"
EVToEBITDA="-1.248"
Beta="0.783"
num_52WeekHigh="2.77"
num_52WeekLow="0.15"
num_50DayMovingAverage="0.24"
num_200DayMovingAverage="0.63"
SharesOutstanding="36240300"
DividendDate="None"
ExDividendDate="None"
symbol="ARDS"
open="0.35"
high="0.35"
low="0.31"
price="0.32"
volume="569782.00"
latest_trading_day="2023-07-14"
previous_close="0.35"
change="-0.03"
change_percent="-9.1453%"
aroon_positive_momentum_days="25"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="25"
Volume_recent_avg="2924299"
Change_recent_avg="-0.01"
Delta_recent_avg="0.04"
Variance_recent_avg="0.02"
Change_ratio_recent_avg="-1.45"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="25"
Aroon_momentum_negative="75"
image_negative_thumbnail_id_1="519"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0086.jpeg"
image_negative_thumbnail_id_2="1112"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0145.jpeg"
image_neutral_thumbnail_id_1="571"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0028.jpeg"
image_neutral_thumbnail_id_2="580"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0019.jpeg"
image_positive_thumbnail_id_1="1011"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0173.jpeg"
image_positive_thumbnail_id_2="611"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0097.jpeg"
image_professor_thumbnail_id_1="1203"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0037.jpeg"
image_professor_thumbnail_id_2="1177"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0011.jpeg"
